Neel H B, Pearson G R, Taylor W F
Ann Otol Rhinol Laryngol. 1984 Sep-Oct;93(5 Pt 1):477-82. doi: 10.1177/000348948409300513.
One hundred fifty-one patients with nasopharyngeal carcinoma (NPC) were enrolled in a prospective collaborative study of North American patients (most were white). Serum samples were collected concurrently from 903 Mayo patients for comparisons of serologic analyses. Both IgA antiviral capsid antigen [VCA (IgA)] and the anti-early antigen [EA (D)] antibody responses were associated with diagnosis, but not always in the same way. Both responses were positive in 85% of patients with World Health Organization types 2 and 3 NPC. Only 16% with WHO type 1 NPC had positive IgA responses and only 35% had positive EA (D) responses, prevalences close to those in the comparison groups. Increased titers were found in the squamous carcinoma comparison group with tumors of the tongue and in the group with benign nasal polyps (p less than 0.01). We believe that the tests are specific, sensitive, and useful in diagnosis and treatment planning in patients with NPC, particularly those with occult primary NPC.
151例鼻咽癌（NPC）患者参与了一项针对北美患者（大多数为白人）的前瞻性合作研究。同时收集了903例梅奥患者的血清样本用于血清学分析比较。IgA抗病毒衣壳抗原[VCA（IgA）]和抗早期抗原[EA（D）]抗体反应均与诊断相关，但方式并不总是相同。在世界卫生组织2型和3型NPC患者中，两种反应均为阳性的占85%。世界卫生组织1型NPC患者中只有16%的IgA反应呈阳性，只有35%的EA（D）反应呈阳性，其患病率与比较组相近。在舌部肿瘤的鳞状细胞癌比较组和鼻息肉良性组中发现滴度升高（p<0.01）。我们认为这些检测在NPC患者，尤其是隐匿性原发性NPC患者的诊断和治疗规划中具有特异性、敏感性且有用。
